Search Results

Niraparib 100 mg  | 99.48%

TargetMol

MK-4827(Niraparib) is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1.

More Information Supplier Page

Niraparib 25 mg  | 99.48%

TargetMol

MK-4827(Niraparib) is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1.

More Information Supplier Page

Selexipag 25 mg  | Purity Not Available

TargetMol

Selexipag(NS-304) is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH).

More Information Supplier Page

JNJ-42165279 25 mg  | 99.89%

TargetMol

JNJ-42165279 covalently inactivates the FAAH enzyme but is highly selective with regard to other enzymes, ion channels, transporters, and receptors. JNJ-42165279 (10 μM) exhibits high selectivity against a panel of 50 receptors, enzymes, transporters, and ion-channels, at which concentration it does not produce >50% inhibition of binding to any of the targets. Fortunately, JNJ-42165279 (10 […]

More Information Supplier Page

JNJ-42165279 2 mg  | 99.89%

TargetMol

JNJ-42165279 covalently inactivates the FAAH enzyme but is highly selective with regard to other enzymes, ion channels, transporters, and receptors. JNJ-42165279 (10 μM) exhibits high selectivity against a panel of 50 receptors, enzymes, transporters, and ion-channels, at which concentration it does not produce >50% inhibition of binding to any of the targets. Fortunately, JNJ-42165279 (10 […]

More Information Supplier Page

AMG-337 2 mg  | 99.82%

TargetMol

AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337(AMG337) inhibits MET kinase activity (IC50: < 5 nM).

More Information Supplier Page

Avitinib 2 mg  | 100.00%

TargetMol

Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This […]

More Information Supplier Page